Non-alcoholic fatty liver disease (NAFLD), insulin resistance and lipid profile in antiepileptic drug treatment

Epilepsy Research

Volumn 86, Issue 1, 2009, Pages 42-47

  Luef, G ^a   Rauchenzauner, M ^a   Waldmann, M ^a   Sturm, W ^a   Sandhofer, A ^a   Seppi, K ^a   Trinka, E ^a   Unterberger, I ^a   Ebenbichler, C F ^a   Joannidis, M ^a   Walser, G ^a   Bauer, G ^a   Hoppichler, F ^b   Lechleitner, M ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b Special Institute for Preventive Cardiology and Nutrition   (Austria)

Author keywords

Carbamazepine; Fatty liver; Hepatotoxicity; Insulin resistance; Valproate

Indexed keywords

CARBAMAZEPINE; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LAMOTRIGINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; VALPROIC ACID;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET RESTRICTION; DYSLIPIDEMIA; ECHOGRAPHY; FEMALE; FOCAL EPILEPSY; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENERALIZED EPILEPSY; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL;

ABDOMEN; ADULT; ANTICONVULSANTS; BLOOD GLUCOSE; BODY MASS INDEX; CHOLESTEROL, HDL; CHOLESTEROL, LDL; EPILEPSY, GENERALIZED; FATTY LIVER; FEMALE; HUMANS; INSULIN RESISTANCE; LIPIDS; LIVER FUNCTION TESTS; MALE; ULTRASONOGRAPHY; YOUNG ADULT;

EID: 68749098182     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2009.04.004     Document Type: Article

References (40)

1. Becker C.M., and Harris R.A. Influence of valproic acid on hepatic carbohydrate and lipid metabolism. Arch. Biochem. Biophys. 223 (1983) 381-392
2. Bellentani S., Saccoccio G., Masutti F., Croce L.S., Brandi G., Sasso F., Cristanini G., and Tiribelli C. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann. Intern. Med. 132 (2000) 112-117
3. Biton V., Mirza W., Montouris G., Vuong A., Hammer A.E., and Barrett P.S. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology 56 (2001) 172-177
4. Bjorge S.M., and Baillie T.A. Inhibition of medium-chain fatty acid beta-oxidation in vitro by valproic acid and its unsaturated metabolite 2-n-propyl-4-pentenoic acid. Biochem. Biophys. Res. Commun. 132 (1985) 245-252
5. Bonora E., Targher G., Alberiche M., Bonadonna R.C., Saggiani F., Zenere M.B., Monauni T., and Muggeo M. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 23 (2000) 57-63
6. Bramswig S., Kerksiek A., Sudhop T., Luers C., Von Bergmann K., and Berthold H.K. Carbamazepine increases atherogenic lipoproteins: mechanism of action in male adults. Am. J. Physiol. Heart Circ. Physiol. 282 (2002) H704-716
7. Draye J.P., and Vamecq J. The inhibition by valproic acid of the mitochondrial oxidation of monocarboxylic and omega-hydroxymonocarboxylic acids: possible implications for the metabolism of gamma-aminobutyric acid. J. Biochem. 102 (1987) 235-242
8. El-Khatib F., Rauchenzauner M., Lechleitner M., Hoppichler F., Naser A., Waldmann M., Trinka E., Unterberger I., Bauer G., and Luef G.J. Valproate, weight gain and carbohydrate craving: a gender study. Seizure 16 (2007) 226-232
9. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18 (1972) 499-502
10. Hayasaka K., Takahashi I., Kobayashi Y., Iinuma K., Narisawa K., and Tada K. Effects of valproate on biogenesis and function of liver mitochondria. Neurology 36 (1986) 351-356
11. Isojarvi J.I., Laatikainen T.J., Knip M., Pakarinen A.J., Juntunen K.T., and Myllyla V.V. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann. Neurol. 39 (1996) 579-584
12. Isojarvi J.I., Rattya J., Myllyla V.V., Knip M., Koivunen R., Pakarinen A.J., Tekay A., and Tapanainen J.S. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann. Neurol. 43 (1998) 446-451
13. Joy D., Thava V.R., and Scott B.B. Diagnosis of fatty liver disease: is biopsy necessary?. Eur. J. Gastroenterol. Hepatol. 15 (2003) 539-543
14. Lee R.G. Non-alcoholic steatohepatitis: tightening the morphological screws on a hepatic rambler. Hepatology 21 (1995) 1742-1743
15. Luef G., Abraham I., Haslinger M., Trinka E., Seppi K., Unterberger I., Alge A., Windisch J., Lechleitner M., and Bauer G. Polycystic ovaries, obesity and insulin resistance in women with epilepsy. A comparative study of carbamazepine and valproic acid in 105 women. J. Neurol. 249 (2002) 835-841
16. Luef G.J., Waldmann M., Sturm W., Naser A., Trinka E., Unterberger I., Bauer G., and Lechleitner M. Valproate therapy and non-alcoholic fatty liver disease. Ann. Neurol. 55 (2004) 729-732
17. Marchesini G., Brizi M., Bianchi G., Tomassetti S., Bugianesi E., Lenzi M., McCullough A.J., Natale S., Forlani G., and Melchionda N. Non-alcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50 (2001) 1844-1850
18. McCullough A.J. Update on non-alcoholic fatty liver disease. J. Clin. Gastroenterol. 34 (2002) 255-262
19. Melegh B., Kerner J., Kispal G., Acsadi G., and Dani M. Effect of chronic valproic acid treatment on plasma and urine carnitine levels in children: decreased urinary excretion. Acta Paediatr. Hung. 28 (1987) 137-142
20. Mortensen P.B., Gregersen N., Kolvraa S., and Christensen E. The occurrence of C6-C10-dicarboxylic acids in urine from patients and rats treated with dipropylacetate. Biochem. Med. 24 (1980) 153-161
21. Mulhall B.P., Ong J.P., and Younossi Z.M. Non-alcoholic fatty liver disease: an overview. J. Gastroenterol. Hepatol. 17 (2002) 1136-1143
22. Murakami K., Sugimoto T., Nishida N., Woo M., Araki A., Kobayashi Y., and Sakane Y. Carnitine metabolism and morphometric change of liver mitochondria in valproate-treated rats. Neuropediatrics 21 (1990) 187-190
23. Patsch W., Brown S.A., Morrisett J.D., Gotto Jr. A.M., and Patsch J.R. A dual-precipitation method evaluated for measurement of cholesterol in high-density lipoprotein subfractions HDL2 and HDL3 in human plasma. Clin. Chem. 35 (1989) 265-270
24. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 16 (2002) 695-714
25. Ponchaut S., Draye J.P., Veitch K., and Van Hoof F. Influence of chronic administration of valproate on ultrastructure and enzyme content of peroxisomes in rat liver and kidney. Oxidation of valproate by liver peroxisomes. Biochem. Pharmacol. 41 (1991) 1419-1428
26. Preiss D., and Sattar N. Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clin. Sci. (Lond.) 115 (2008) 141-150
27. Pylvanen V., Knip M., Pakarinen A., Kotila M., Turkka J., and Isojarvi J.I. Serum insulin and leptin levels in valproate-associated obesity. Epilepsia 43 (2002) 514-517
28. Pylvanen V., Knip M., Pakarinen A.J., Turkka J., Kotila M., Rattya J., Myllyla V.V., and Isojarvi J.I. Fasting serum insulin and lipid levels in men with epilepsy. Neurology 60 (2003) 571-574
29. Rauchenzauner M., Haberlandt E., Scholl-Burgi S., Ernst B., Hoppichler F., Karall D., Ebenbichler C.F., Rostasy K., and Luef G. Adiponectin and visfatin concentrations in children treated with valproic acid. Epilepsia 49 (2008) 353-357
30. Rauchenzauner M., Haberlandt E., Scholl-Burgi S., Karall D., Schoenherr E., Tatarczyk T., Engl J., Laimer M., Luef G., and Ebenbichler C.F. Effect of valproic acid treatment on body composition, leptin and the soluble leptin receptor in epileptic children. Epilepsy Res. 80 (2008) 142-149
31. Rauchenzauner M., Laimer M., Luef G., Kaser S., Engl J., Tatarczyk T., Ciardi C., Tschoner A., Lechleitner M., Patsch J., and Ebenbichler C.F. Adiponectin receptor R1 is upregulated by valproic acid but not by topiramate in human hepatoma cell line. HepG2. Seizure 17 (2008) 723-726
32. Reaven G. Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation 106 (2002) 286-288
33. Saadeh S., Younossi Z.M., Remer E.M., Gramlich T., Ong J.P., Hurley M., Mullen K.D., Cooper J.N., and Sheridan M.J. The utility of radiological imaging in non-alcoholic fatty liver disease. Gastroenterology 123 (2002) 745-750
34. Sanyal A.J., Campbell-Sargent C., Mirshahi F., Rizzo W.B., Contos M.J., Sterling R.K., Luketic V.A., Shiffman M.L., and Clore J.N. Non-alcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120 (2001) 1183-1192
35. Scheen A.J., and Luyckx F.H. Obesity and liver disease. Best Pract. Res. Clin. Endocrinol. Metab. 16 (2002) 703-716
36. Stiemer B. Morphological evaluation of steatosis in monolayer cultures (MDCK cells) after treatment with gentamicin and valproic acid. Histol. Histopathol. 4 (1989) 421-428
37. Sugimoto T., Woo M., Nishida N., Takeuchi T., Sakane Y., and Kobayashi Y. Hepatotoxicity in rat following administration of valproic acid. Epilepsia 28 (1987) 142-146
38. Unger R.H., and Orci L. Diseases of liporegulation: new perspective on obesity and related disorders. FASEB J. 15 (2001) 312-321
39. Verrotti A., Basciani F., De Simone M., Trotta D., Morgese G., and Chiarelli F. Insulin resistance in epileptic girls who gain weight after therapy with valproic acid. J. Child Neurol. 17 (2002) 265-268
40. Yilmaz E., Dosan Y., Gurgoze M.K., and Gungor S. Serum lipid changes during anticonvulsive treatment serum lipids in epileptic children. Acta Neurol. Belg. 101 (2001) 217-220